ECM
NBIX icon

Evergreen Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Evergreen Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582K Buy
3,455
+1,248
+57% +$185K 0.01% 823
2026
Q1 		$291K Sell
2,207
-157
-7% -$20.8K 0.01% 1145
2025
Q4 		$335K Sell
2,364
-203
-8% -$29.4K 0.01% 975
2025
Q3 		$360K Buy
+2,567
New +$348K 0.01% 842
2025
Q1 		– Sell
-2,420
Closed -$330K – 1150
2024
Q4 		$330K Buy
+2,420
New +$299K 0.01% 684

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Evergreen Capital Management's NBIX Position: Q2 2026 in Review

Evergreen Capital Management increased its Neurocrine Biosciences (NBIX) stake by 57% in Q2 2026, buying an estimated $185K and bringing the position to 3,455 shares worth $582K. The position accounts for 0.01% of the portfolio, ranked #823.

Evergreen Capital Management first reported a position in NBIX in Q4 2024 and has held it in 5 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Evergreen Capital Management held 3,455 shares of Neurocrine Biosciences worth $582K as of Q2 2026.
  • Evergreen Capital Management bought 1,248 Neurocrine Biosciences shares in Q2 2026, an estimated $185K.
  • Neurocrine Biosciences made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #823 holding.
  • Evergreen Capital Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 5 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.